Brind.

Mesoblast received FDA approval for Ryoncil®, was added to S&P Dow Jones Indices, and appointed a new CEO.

10 reports, 3 independent Updated Aug 26
Gone quiet Reached 2 outlets in its first 24 hours
Reports
10
Developments
3
Repetition
70%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Mesoblast received FDA approval for Ryoncil®, was added to S&P Dow Jones Indices, and appointed a new CEO.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Mesoblast filed for a label extension for Ryoncil®.1 source
  2. Mesoblast secured FDA approval and S&P listing, alongside a CEO change.1 source
  3. CMS coverage for Ryoncil® expanded following FDA approval, enabling commercial launch.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireBanner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil® Financial Results and Operational Update for the Full Year Ended June 30, 2025 NEW YORK, Aug. 28
  • Insider MonkeyCanaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating Mesoblast Limited (NASDAQ:MESO) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, Canaccord Genuit
  • Insider MonkeyMesoblast Limited (MESO) Launches First Cell Therapy for Children We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Mesoblast Limited stands tenth on our list an
  • GlobeNewswireSuccessful Commercial Launch of Ryoncil® Activity Report for Quarter Ended June 30, 2025 (Appendix 4C) NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global lea
  • Unknown outlet
4 more outlets ran the same wire story